NMTC2
MCID: THY102
MIFTS: 58

Thyroid Cancer, Nonmedullary, 2 (NMTC2) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 2

Aliases & Descriptions for Thyroid Cancer, Nonmedullary, 2:

Name: Thyroid Cancer, Nonmedullary, 2 54
Follicular Thyroid Carcinoma 12 50 14 69
Thyroid Carcinoma, Follicular 54 50 13
Thyroid Cancer, Follicular 50 29 69
Follicular Adenocarcinoma, Well Differentiated 12
Follicular Carcinoma of the Thyroid Gland 12
Thyroid Carcinoma, Follicular, Somatic 54
Thyroid Carcinoma, Follicular Somatic 24
Thyroid Cancer, Non-Medullary, 2 66
Thyroid Follicular Carcinoma 52
Thyroid Gland Adenocarcinoma 69
Adenocarcinoma, Follicular 42
Follicular Adenocarcinoma 12
Follicular Thyroid Cancer 52
Thyroid Adenocarcinoma 12
Follicular Carcinoma 12
Nmtc2 66
Ftc 50

Characteristics:

HPO:

32
thyroid cancer, nonmedullary, 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 188470
Disease Ontology 12 DOID:3962
NCIt 47 C8054
MedGen 40 C0206682
UMLS 69 C0206682

Summaries for Thyroid Cancer, Nonmedullary, 2

OMIM : 54 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95%... (188470) more...

MalaCards based summary : Thyroid Cancer, Nonmedullary, 2, also known as follicular thyroid carcinoma, is related to familial papillary or follicular thyroid carcinoma and trabecular follicular adenocarcinoma, and has symptoms including abnormality of metabolism/homeostasis, follicular thyroid carcinoma and non-medullary thyroid carcinoma. An important gene associated with Thyroid Cancer, Nonmedullary, 2 is SRGAP1 (SLIT-ROBO Rho GTPase Activating Protein 1), and among its related pathways/superpathways are Glioma and Ras signaling pathway. The drugs Hydroxocobalamin and Folic Acid have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and bone, and related phenotypes are Decreased viability and endocrine/exocrine gland

Disease Ontology : 12 A thyroid carcinoma that has material basis in follicular cells.

UniProtKB/Swiss-Prot : 66 Thyroid cancer, non-medullary, 2: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Related Diseases for Thyroid Cancer, Nonmedullary, 2

Diseases in the Thyroid Cancer, Nonmedullary, 2 family:

Thyroid Cancer, Nonmedullary, 4 Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Related Disease Score Top Affiliating Genes
1 familial papillary or follicular thyroid carcinoma 12.0
2 trabecular follicular adenocarcinoma 11.9
3 papillary follicular thyroid adenocarcinoma 11.8
4 differentiated thyroid carcinoma 11.3
5 medullary thyroid carcinoma, familial 11.0
6 thyroid carcinoma, hurthle cell 11.0
7 thyroid cancer, monmedullary, 1 10.9
8 thyroid cancer 10.8
9 tumoral calcinosis, hyperphosphatemic, familial 10.8
10 parotid gland adenoid cystic carcinoma 10.4 HRAS NRAS PTEN
11 mesocardia 10.3 PAX8 TG TSHR
12 acute disseminated encephalomyelitis 10.3 BRAF NRAS PTEN
13 background diabetic retinopathy 10.3 TG TPO TSHR
14 endophthalmitis 10.3 CALCA TG
15 cowden syndrome 3 10.3 CALCA RET TG
16 tick paralysis 10.3 TG THRB TPO
17 conjunctival deposit 10.3 TG TPO TSHR
18 mixed eosinophil-basophil adenoma 10.3 TG TPO TSHR
19 childhood teratocarcinoma of the testis 10.3 CALCA PTEN RET TG
20 bizarre leiomyoma 10.3 CALCA NKX2-1 TG
21 monostotic fibrous dysplasia 10.3 BRAF LGALS3 PTEN
22 acute hemorrhagic encephalitis 10.3 HRAS NRAS RET TG TSHR
23 hypothyroidism, congenital, nongoitrous, 1 10.3 TG THRB TPO TSHR
24 neuhauser daly magnelli syndrome 10.3 PAX8 TG TPO TSHR
25 krabbe disease 10.3 CALCA TG TPO TSHR
26 endemic goiter 10.3 CALCA TG TPO TSHR
27 denys-drash syndrome 10.3 TG TPO TSHR
28 neutropenia, severe congenital, 5, autosomal recessive 10.3 CALCA NKX2-1 RET TG
29 malignant pleural solitary fibrous tumor 10.3 HRAS NKX2-1 NRAS PTEN
30 glomangiomyoma 10.3 TG THRB TPO TSHR
31 urinary tract papillary transitional cell benign neoplasm 10.3 CALCA NKX2-1 RET
32 janus kinase-3 deficiency 10.2 TG TPO TSHR
33 pseudomonas stutzeri infections 10.2 BRAF NRAS
34 gastrinoma 10.2 CALCA NKX2-1 RET TG TSHR
35 trigonocephaly, nonsyndromic 10.2 BRAF RET
36 glomeruloid hemangioma 10.2 BRAF HRAS KDR NRAS PTEN
37 neuronopathy, distal hereditary motor, type viia 10.2 LGALS3 NKX2-1 PAX8 TG TSHR
38 parachordoma 10.2 BRAF NKX2-1 RET TG TSHR
39 tmem70 defect 10.2 BRAF NKX2-1 PAX8 RET TG
40 thyroiditis 10.2
41 broad ligament malignant neoplasm 10.2 CALCA DIO2 TG TPO TSHR
42 commensal bacterial infectious disease 10.2 NKX2-1 PAX8 TG TPO TSHR
43 infertility 10.2 HRAS LGALS3 NKX2-1 NRAS RET TG
44 dihydrolipoamide dehydrogenase deficiency 10.2 PAX8 TG TPO
45 pulsating exophthalmos 10.2 DIO2 TG THRB TPO TSHR
46 autoimmune hemolytic anemia 10.2 CALCA RET TG THRB TPO TSHR
47 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 10.2 BRAF HRAS LGALS3 NME1 NRAS PTEN
48 cholesterol embolism 10.1 NKX2-1 PAX8 TG THRB TPO TSHR
49 benign shuddering attacks 10.1 CALCA HRAS KDR LGALS3 PAX8 RET
50 lattice corneal dystrophy 10.1 BRAF NME1 NRAS

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 2:



Diseases related to Thyroid Cancer, Nonmedullary, 2

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 2

Symptoms by clinical synopsis from OMIM:

188470

Clinical features from OMIM:

188470

Human phenotypes related to Thyroid Cancer, Nonmedullary, 2:

32
id Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 32 HP:0001939
2 follicular thyroid carcinoma 32 HP:0006731
3 non-medullary thyroid carcinoma 32 HP:0040198

GenomeRNAi Phenotypes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.6 HRAS
2 Decreased viability GR00221-A-1 9.6 KDR NRAS PPARG RET HRAS
3 Decreased viability GR00221-A-2 9.6 KDR PPARG RET HRAS
4 Decreased viability GR00221-A-3 9.6 KDR NRAS PPARG HRAS
5 Decreased viability GR00221-A-4 9.6 KDR PPARG RET
6 Decreased viability GR00231-A 9.6 RET
7 Decreased viability GR00301-A 9.6 RET

MGI Mouse Phenotypes related to Thyroid Cancer, Nonmedullary, 2:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.46 NME1 NRAS PAX8 PPARG PTEN RASSF1
2 growth/size/body region MP:0005378 10.45 BRAF DIO2 HRAS KDR NKX2-1 NME1
3 homeostasis/metabolism MP:0005376 10.45 NKX2-1 NRAS PAX8 PPARG PTEN RASSF1
4 behavior/neurological MP:0005386 10.39 BRAF HRAS KDR LGALS3 NKX2-1 NRAS
5 cardiovascular system MP:0005385 10.38 BRAF HRAS KDR LGALS3 NKX2-1 NRAS
6 mortality/aging MP:0010768 10.35 HRAS KDR LGALS3 NKX2-1 NME1 BRAF
7 cellular MP:0005384 10.34 BRAF KDR LGALS3 NKX2-1 NRAS PAX8
8 hematopoietic system MP:0005397 10.3 KDR LGALS3 NRAS PPARG PTEN RET
9 immune system MP:0005387 10.28 BRAF KDR LGALS3 NRAS PPARG PTEN
10 nervous system MP:0003631 10.25 BRAF HRAS KDR LGALS3 NKX2-1 NME1
11 digestive/alimentary MP:0005381 10.24 BRAF DIO2 LGALS3 NKX2-1 NRAS PTEN
12 neoplasm MP:0002006 10.23 BRAF HRAS LGALS3 NKX2-1 NME1 NRAS
13 integument MP:0010771 10.13 NME1 NRAS PPARG PTEN BRAF HRAS
14 normal MP:0002873 10.11 PTEN RASSF1 RET BRAF HRAS KDR
15 liver/biliary system MP:0005370 10.1 BRAF KDR LGALS3 NME1 NRAS PPARG
16 limbs/digits/tail MP:0005371 10.05 NRAS PAX8 PTEN RET THRB TPO
17 hearing/vestibular/ear MP:0005377 10.04 BRAF PAX8 PPARG THRB TPO TSHR
18 no phenotypic analysis MP:0003012 10.01 HRAS KDR NKX2-1 NRAS PAX8 PPARG
19 renal/urinary system MP:0005367 9.92 PAX8 PPARG PTEN RET BRAF DIO2
20 reproductive system MP:0005389 9.91 TSHR BRAF LGALS3 NKX2-1 PAX8 PPARG
21 respiratory system MP:0005388 9.76 BRAF HRAS KDR LGALS3 NKX2-1 PTEN
22 skeleton MP:0005390 9.73 BRAF DIO2 HRAS KDR LGALS3 NKX2-1
23 vision/eye MP:0005391 9.28 PTEN THRB TPO TSHR BRAF KDR

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 2

Drugs for Thyroid Cancer, Nonmedullary, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
2
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
3
leucovorin Approved, Nutraceutical Phase 4,Phase 2 58-05-9 54575, 6560146 143
4
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
5
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
6 Hypoglycemic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
7 Vitamin B Complex Phase 4,Phase 3,Phase 2
8 Hematinics Phase 4
9 insulin Phase 4
10 Insulin, Globin Zinc Phase 4
11 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
12 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
13 Vitamin B 12 Phase 4
14 Vitamins Phase 4,Phase 3,Phase 2
15 cadexomer iodine Phase 4,Phase 3,Phase 2,Phase 1
16 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19
Iodine Phase 4,Phase 3,Phase 2,Phase 1 7553-56-2 807
20 Folate Nutraceutical Phase 4,Phase 3,Phase 2
21 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2
22
Cobalamin Nutraceutical Phase 4 13408-78-1 6438156
23 Inositol Nutraceutical Phase 4
24
Methylcobalamin Experimental, Nutraceutical Phase 4 13422-55-4
25 Vitamin B12 Nutraceutical Phase 4
26
Salmon Calcitonin Approved, Investigational Phase 3,Phase 2 47931-85-1 16129616
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
28
rituximab Approved Phase 3,Phase 1 174722-31-7 10201696
29
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
30
Progesterone Approved, Vet_approved Phase 3,Early Phase 1 57-83-0 5994
31
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
32
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2 98-92-0 936
33
Cholecalciferol Approved, Nutraceutical Phase 3,Phase 2 67-97-0 6221 10883523 5280795
34
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
35 Liver Extracts Phase 3,Phase 2,Phase 1
36 Anti-Infective Agents Phase 3,Phase 2,Phase 1
37 Antirheumatic Agents Phase 3,Phase 2,Phase 1
38 Bone Density Conservation Agents Phase 3,Phase 2
39 calcitonin Phase 3,Phase 2
40 Calcitonin Gene-Related Peptide Phase 3,Phase 2
41 Adjuvants, Anesthesia Phase 3
42 Analgesics Phase 3,Phase 2
43 Analgesics, Opioid Phase 3
44 Anesthetics Phase 3
45 Anesthetics, General Phase 3
46 Anesthetics, Intravenous Phase 3
47 Central Nervous System Depressants Phase 3,Phase 2
48 Narcotics Phase 3
49 pancreatic polypeptide Phase 3,Phase 1
50 Peripheral Nervous System Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 115)
id Name Status NCT ID Phase
1 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4
2 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4
3 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
5 Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Completed NCT00268983 Phase 3
6 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
7 Iodine I 131 With or Without Thyroid-Stimulating Hormone in Treating Patients Who Have Undergone Surgery for Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
8 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Active, not recruiting NCT00984282 Phase 3
9 Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer Active, not recruiting NCT01608451 Phase 3
10 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2
11 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2
12 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
13 Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer Unknown status NCT00786552 Phase 2
14 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2
15 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2
16 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer Completed NCT00251316 Phase 2
17 Thalidomide in Treating Patients With Thyroid Cancer Completed NCT00026533 Phase 2
18 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2
19 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2
20 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
21 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2
22 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2
23 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2
24 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2
25 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2
26 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2
27 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2
28 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2
29 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2
30 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2
31 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2
32 Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer Completed NCT00365287 Phase 1, Phase 2
33 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2
34 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors Completed NCT00004157 Phase 2
35 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2
36 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer Completed NCT00003408 Phase 2
37 A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin Completed NCT01182285 Phase 2
38 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed NCT00559949 Phase 2
39 Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer Completed NCT00389441 Phase 2
40 Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab Completed NCT00933335 Phase 2
41 Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant Completed NCT00321932 Phase 2
42 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2
43 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2
44 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2
45 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2
46 Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study Recruiting NCT02084732 Phase 2
47 REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas Active, not recruiting NCT00287287 Phase 2
48 Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer Active, not recruiting NCT00537095 Phase 2
49 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting NCT01723202 Phase 2
50 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 2

Cochrane evidence based reviews: adenocarcinoma, follicular

Genetic Tests for Thyroid Cancer, Nonmedullary, 2

Genetic tests related to Thyroid Cancer, Nonmedullary, 2:

id Genetic test Affiliating Genes
1 Thyroid Cancer, Follicular 29
2 Follicular Thyroid Carcinoma 29
3 Thyroid Carcinoma, Follicular Somatic 24 PTEN

Anatomical Context for Thyroid Cancer, Nonmedullary, 2

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 2:

39
Thyroid, Lung, Bone, Lymph Node

Publications for Thyroid Cancer, Nonmedullary, 2

Variations for Thyroid Cancer, Nonmedullary, 2

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

66
id Symbol AA change Variation ID SNP ID
1 HRAS p.Gln61Lys VAR_045979 rs28933406
2 MINPP1 p.Ser41Leu VAR_022836 rs119486096
3 MINPP1 p.Gln270Arg VAR_022837 rs104894171
4 NRAS p.Gln61Arg VAR_006847 rs11554290
5 SRGAP1 p.Gln149His VAR_075879 rs781626187
6 SRGAP1 p.Ala275Thr VAR_075880 rs797044990
7 SRGAP1 p.Arg617Cys VAR_075882 rs114817817
8 SRGAP1 p.His875Arg VAR_075883 rs61754221

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 MINPP1 NM_004897.4(MINPP1): c.122C> T (p.Ser41Leu) single nucleotide variant Pathogenic rs119486096 GRCh37 Chromosome 10, 89264794: 89264794
2 MINPP1 NM_004897.4(MINPP1): c.809A> G (p.Gln270Arg) single nucleotide variant Pathogenic rs104894171 GRCh37 Chromosome 10, 89268264: 89268264
3 HRAS NM_005343.3(HRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933406 GRCh37 Chromosome 11, 533875: 533875
4 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
5 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
6 SRGAP1 NM_020762.3(SRGAP1): c.447A> C (p.Gln149His) single nucleotide variant Pathogenic rs781626187 GRCh38 Chromosome 12, 64016970: 64016970
7 SRGAP1 NM_020762.3(SRGAP1): c.823G> A (p.Ala275Thr) single nucleotide variant Pathogenic rs797044990 GRCh38 Chromosome 12, 64062938: 64062938
8 SRGAP1 NM_020762.3(SRGAP1): c.1849C> T (p.Arg617Cys) single nucleotide variant risk factor rs114817817 GRCh37 Chromosome 12, 64502747: 64502747

Cosmic variations for Thyroid Cancer, Nonmedullary, 2:

9 (show top 50) (show all 161)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM26449 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1358T>C p.M453T 29
2 COSM26419 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1897G>T p.D633Y 29
3 COSM26450 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1456A>T p.I486F 29
4 COSM26485 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1894A>G p.T632A 29
5 COSM26418 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1895C>T p.T632I 29
6 COSM26455 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1891T>A p.F631I 29
7 COSM10656 TP53 thyroid,NS,carcinoma,follicular carcinoma c.742C>T p.R248W 29
8 COSM43624 TP53 thyroid,NS,carcinoma,follicular carcinoma c.875A>G p.K292R 29
9 COSM5546625 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.767A>T p.Q256L 29
10 COSM1570338 RET thyroid,NS,carcinoma,follicular carcinoma c.2651A>T p.E884V 29
11 COSM5546623 RB1 thyroid,NS,carcinoma,follicular carcinoma c.2039T>C p.I680T 29
12 COSM5224 PTEN thyroid,NS,carcinoma,follicular carcinoma c.370T>A p.C124S 29
13 COSM23654 PTEN thyroid,NS,carcinoma,follicular carcinoma c.701G>A p.R234Q 29
14 COSM23651 PTEN thyroid,NS,carcinoma,follicular carcinoma c.353A>G p.H118R 29
15 COSM23652 PTEN thyroid,NS,carcinoma,follicular carcinoma c.496G>A p.V166I 29
16 COSM23653 PTEN thyroid,NS,carcinoma,follicular carcinoma c.476G>A p.R159K 29
17 COSM5033 PTEN thyroid,NS,carcinoma,follicular carcinoma c.389G>A p.R130Q 29
18 COSM28547 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3180C>T p.H1060H 29
19 COSM29097 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.1649T>C p.F550S 29
20 COSM33598 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3002T>A p.L1001H 29
21 COSM33600 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3046T>C p.F1016L 29
22 COSM29095 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3001C>A p.L1001I 29
23 COSM12458 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.1634A>C p.E545A 29
24 COSM28544 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3026G>A p.G1009E 29
25 COSM33599 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3052G>A p.D1018N 29
26 COSM29096 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.1558G>A p.D520N 29
27 COSM33601 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3155C>T p.T1052I 29
28 COSM580 NRAS thyroid,NS,carcinoma,follicular carcinoma c.181C>A p.Q61K 29
29 COSM551 KRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>C p.Q61P 29
30 COSM552 KRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>G p.Q61R 29
31 COSM516 KRAS thyroid,NS,carcinoma,follicular carcinoma c.34G>T p.G12C 29
32 COSM532 KRAS thyroid,NS,carcinoma,follicular carcinoma c.38G>A p.G13D 29
33 COSM522 KRAS thyroid,NS,carcinoma,follicular carcinoma c.35G>C p.G12A 29
34 COSM518 KRAS thyroid,NS,carcinoma,follicular carcinoma c.34G>C p.G12R 29
35 COSM96532 IDH1 thyroid,NS,carcinoma,follicular carcinoma c.390A>G p.I130M 29
36 COSM96533 IDH1 thyroid,NS,carcinoma,follicular carcinoma c.399T>A p.H133Q 29
37 COSM499 HRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>G p.Q61R 29
38 COSM500 HRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>C p.Q61P 29
39 COSM496 HRAS thyroid,NS,carcinoma,follicular carcinoma c.181C>A p.Q61K 29
40 COSM485 HRAS thyroid,NS,carcinoma,follicular carcinoma c.35G>C p.G12A 29
41 COSM484 HRAS thyroid,NS,carcinoma,follicular carcinoma c.35G>A p.G12D 29
42 COSM498 HRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>T p.Q61L 29
43 COSM27895 GNAS thyroid,NS,carcinoma,follicular carcinoma c.602G>A p.R201H 29
44 COSM27900 GNAS thyroid,NS,carcinoma,follicular carcinoma c.681G>T p.Q227H 29
45 COSM28618 GNAS thyroid,NS,carcinoma,follicular carcinoma c.679C>A p.Q227K 29
46 COSM13224 CDKN2A thyroid,NS,carcinoma,follicular carcinoma c.242C>T p.P81L 29
47 COSM1570337 ALK thyroid,NS,carcinoma,follicular carcinoma c.3551G>A p.G1184E 29
48 COSM17721 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 26
49 COSM26416 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 26
50 COSM44225 TP53 thyroid,NS,carcinoma,papillary carcinoma c.859G>A p.E287K 26

Expression for Thyroid Cancer, Nonmedullary, 2

Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 2.

Pathways for Thyroid Cancer, Nonmedullary, 2

Pathways related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 BRAF HRAS KDR NRAS PTEN RASSF1
2
Show member pathways
12.64 BRAF HRAS KDR NRAS RASSF1
3
Show member pathways
12.38 BRAF HRAS KDR NRAS PTEN
4
Show member pathways
12.32 PAX8 TG TPO TSHR
5
Show member pathways
12.29 BRAF HRAS NRAS PTEN
6
Show member pathways
12.26 BRAF HRAS NRAS PTEN
7 12.2 BRAF HRAS KDR NRAS
8
Show member pathways
12.17 BRAF HRAS NRAS PPARG
9 12.15 BRAF HRAS NRAS PAX8 PPARG PTEN
10
Show member pathways
12.11 HRAS KDR NRAS PTEN
11
Show member pathways
12.06 BRAF HRAS NRAS PPARG
12
Show member pathways
11.96 BRAF HRAS NRAS PTEN
13 11.84 DIO2 HRAS NRAS THRB
14 11.78 BRAF HRAS NRAS PTEN
15
Show member pathways
11.57 BRAF HRAS NRAS
16 11.57 BRAF HRAS NRAS RASSF1
17 11.52 BRAF HRAS NRAS
18 11.5 BRAF HRAS PAX8 TSHR
19
Show member pathways
11.47 BRAF HRAS KDR NRAS RET
20 11.44 HRAS NRAS PTEN RET
21 11.39 HRAS NRAS RET
22 11.2 BRAF HRAS NRAS
23 11.11 HRAS NRAS PTEN
24 10.74 HRAS NRAS
25 10.56 BRAF HRAS NRAS PAX8 PPARG RET
26 10.21 TG TPO TSHR

GO Terms for Thyroid Cancer, Nonmedullary, 2

Biological processes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.96 BRAF HRAS NRAS PPARG RASSF1 RET
2 MAPK cascade GO:0000165 9.85 BRAF HRAS NRAS RET
3 axon guidance GO:0007411 9.8 HRAS NKX2-1 NRAS RET
4 positive regulation of gene expression GO:0010628 9.8 BRAF HRAS NKX2-1 PTEN RET
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.73 BRAF HRAS KDR PTEN
6 Ras protein signal transduction GO:0007265 9.69 HRAS NRAS RASSF1
7 animal organ morphogenesis GO:0009887 9.62 BRAF HRAS NKX2-1 THRB
8 thyroid hormone generation GO:0006590 9.54 DIO2 TPO
9 cellular response to nerve growth factor stimulus GO:1990090 9.54 BRAF CALCA PTEN
10 positive regulation of adenylate cyclase activity GO:0045762 9.52 CALCA TSHR
11 thyroid hormone metabolic process GO:0042403 9.48 DIO2 TG
12 regulation of axon regeneration GO:0048679 9.46 BRAF PTEN
13 thyroid-stimulating hormone signaling pathway GO:0038194 9.16 PAX8 TSHR
14 hormone biosynthetic process GO:0042446 9.13 DIO2 TG TPO
15 thyroid gland development GO:0030878 8.92 BRAF NKX2-1 PAX8 TG

Molecular functions related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity GO:0051717 8.96 MINPP1 PTEN
2 thyroid-stimulating hormone receptor activity GO:0004996 8.62 PAX8 TSHR

Sources for Thyroid Cancer, Nonmedullary, 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....